Endocyte's ABX Deal To Serve As Springboard For Radioligand Pipeline

02 Oct 2017

• By Emily Hayes

Company gains worldwide rights to mid-stage therapy 177Lu-PSMA-617, which would compete with Bayer/Algeta's radiopharmaceutical Xofigo in metastatic castration-resistant prostate cancer.

businessman and businesswoman are shaking hands and exchanging folder after agreement was reached

Endocyte Inc.intends to use a deal to acquire worldwide rights for the prostate cancer therapeutic 177 Lu-PSMA-617 from ABX SA in Germany as a springboard for building a pipeline of radioligand therapeutics.

Endocyte described the deal in a statement as "transformational… accelerating our path to commercialization." The company is looking to get feedback from the US FDA to start a Phase III...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Bristol Will Pay BioNTech $1.5bn Up Front To Enter PD-L1xVEGF Space

02 Jun 2025

• By Joseph Haas

BMS is guaranteeing BioNTech at least $3.5bn to share development costs and potential profits on the Phase III bispecific, to compete with Summit, Merck and Pfizer.

Regeneron Buys Tirzepatide-Like Product With Eye On Muscle-Preserving Combinations

02 Jun 2025

• By Jessica Merrill

Regeneron is bringing in its own GIP/GLP-1 agonist, establishing a path to develop proprietary obesity drug combinations with its internal muscle-sparing drugs.